Lyra Therapeutics raises $29.5M for chronic rhinosinusitis drug implant
The company plans to use the funding to advance LYR-210 into a Phase II clinical trial and also explore its development platform in other ENT diseases.
The company plans to use the funding to advance LYR-210 into a Phase II clinical trial and also explore its development platform in other ENT diseases.
The oversubscribed round comes just four months after acquisition of GSK's gene therapy portfolio.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.